Changing the regulations: Hope dies last. [NCA / SHAM]

posted by PharmCat  – Russia, 2021-10-01 20:48 (988 d 18:17 ago) – Posting: # 22613
Views: 2,867

❝ Hhm, can you elaborate?


these are my thoughts, I did not support them with any deep search ...
$$C = C_0 * e^{-k_e * t}$$ => $$C = \frac{D}{V_d} * e^{-k_e * t}$$
Model:
$$C = \frac{aX + \epsilon_2}{V_d} * e^{-bZ * t} * \epsilon_1 $$
$$ \epsilon_1 \sim N(0, \sigma_1^2); \epsilon_2 \sim N(0, \sigma_2^2)$$
It can be solved for \(a, V_d, b, \sigma_1^2, \sigma_2^2\) and modified for extravascular model.

Something described here: Korkmaz, Selcuk & Orman, Mehmet. (2012). The Use of Nonlinear Mixed Effects Models in Bioequivalence Studies: A Real Data Application. Open Access Scientific Reports. 1-11

However, I think terminal-phase adjusted area under the concentration curve method is something between the classic and NLME approaches. And both of them make corrections for variation from elimination.

Complete thread:

UA Flag
Activity
 Admin contact
23,056 posts in 4,840 threads, 1,641 registered users;
163 visitors (0 registered, 163 guests [including 136 identified bots]).
Forum time: 15:06 CEST (Europe/Vienna)

My definition of an expert in any field
is a person who knows enough
about what’s really going on
to be scared.    Phillip J. Plauger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5